Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cyclacel Pharmaceuticals Inc
CYCCP
Primary Symbol:
CYCC
Healthcare
Biotechnology
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic...
program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CYCC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 02, 2024 3:24am
Cyclacel Pharmaceuticals (CYCC): A Promising Oncology Biotec
https://beyondspx.com/2024/08/01/cyclacel-pharmaceuticals-cycc-a-promising-oncology-biotech-with-exciting-pipeline-developments/
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 14, 2024 4:05pm
New Press Release - Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib - - First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study - - Balance Sheet Bolstered with $8.0 million Private Placement Priced At-The...
read article.
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 08, 2024 11:00am
Cyclacel Pharmaceuticals to Release First Quarter 2024 Finan
News; $CYCCP Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsBERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 08, 2024 9:15am
New Press Release - Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 02, 2024 4:30pm
New Press Release - Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 30, 2024 7:00am
New Press Release - Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 25, 2024 1:58pm
CYCC.....FOMO's wanted....sign up to the Chasers list
JMHO
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 25, 2024 1:57pm
CYCC.....zero volume at the low
No the bottom feeders are offing their paper
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 25, 2024 1:26pm
CYCC....N.L.O.D $1.41
Yesterdays vol & price action was just a Pump & Dump by none other than the Infamous Mr. Maggot !!!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 25, 2024 12:22pm
CYCC....N.L.O.D.....$1.59
Ya have to be ready for these RS thinners throwing everyone a "curveball" Market Makers are throwing a few of these lately
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 25, 2024 9:45am
CYCC....I am totally rid of this
sec.gov/Archives/edgar/data/1130166/000110465924051334/tm249520d5_s1.htm
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 01, 2024 9:15am
New Press Release - Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 27, 2024 2:15pm
CYCC....still watching this Mr. maggot ; )
Whack that bid.... need some cheap paper ; ) Sub $1.75 would be nice. Thanks for your manipulative endeavours
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Mar 26, 2024 3:10pm
RE:CYCC....trading by appt only....Lol
Seems to me Mr. M can intercept any shares from weak hands selling It's not a level playing field...hehe
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Mar 26, 2024 3:08pm
CYCC....trading by appt only....Lol
200 shs trade in between bid & ask Amazing how that works
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >